Literature DB >> 7818262

Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity.

P Rieckmann1, M Albrecht, B Kitze, T Weber, H Tumani, A Broocks, W Lüer, A Helwig, S Poser.   

Abstract

We determined the cytokine messenger RNA (mRNA) expression pattern of blood mononuclear cells in 29 patients with relapsing-remitting multiple sclerosis every 4 weeks over a period of 12 months. During this period 27 relapses occurred in 14 patients (48%). Progression of disease activity as assessed by the occurrence of new lesions on nonenhancing T2-weighted magnetic resonance images of the head was detected in 12 (48%) of 25 patients. Using a semiquantitative polymerase chain reaction we demonstrated significant increases in tumor necrosis factor-alpha mRNA expression in peripheral blood mononuclear cells prior to a relapse. In 24 (85%) of 27 relapses increased tumor necrosis factor-alpha mRNA expression preceded clinical symptoms by 4 weeks. A similar pattern was observed for lymphotoxin mRNA expression. At the same time, transforming growth factor-beta and interleukin-10 mRNA levels declined. Fluctuations in the mRNA expression of tumor necrosis factor-alpha were also observed in 6 patients with stable disease who had active magnetic resonance scans on follow-up. No correlation of disease activity was observed with interleukin-1 beta, -4, or -6, inferferon gamma or endothelin-1 mRNA expression. From these data it can be concluded that variations in cytokine mRNA expression in blood mononuclear cells are correlated with disease activity in relapsing-remitting multiple sclerosis. It may be a valuable parameter to monitor the immunological status of patients in future clinical trials.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7818262     DOI: 10.1002/ana.410370115

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  56 in total

1.  Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis.

Authors:  M E Smith; N L Eller; H F McFarland; M K Racke; C S Raine
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

Review 2.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

3.  Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis.

Authors:  Charlotte Angerstein; Michael Hecker; Brigitte Katrin Paap; Dirk Koczan; Madhan Thamilarasan; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2012-05-02       Impact factor: 5.590

4.  Correlation between interferon production and clinical disease activity in patients with multiple sclerosis.

Authors:  M Dettke; P Scheidt; H Prange; H Kirchner
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

5.  Interferon-gamma induced increases in intracellular calcium in T lymphocytes from patients with multiple sclerosis precede clinical exacerbations and detection of active lesions on MRI.

Authors:  G Martino; M Filippi; V Martinelli; E Brambilla; C Gobbi; G Comi; L M Grimaldi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

Review 6.  Monoclonal antibodies as disease modifying therapy in multiple sclerosis.

Authors:  Erin E Longbrake; Becky J Parks; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

7.  The SWI/SNF chromatin-remodeling complex modulates peripheral T cell activation and proliferation by controlling AP-1 expression.

Authors:  Seung Min Jeong; Changjin Lee; Sung Kyu Lee; Jieun Kim; Rho Hyun Seong
Journal:  J Biol Chem       Date:  2009-11-12       Impact factor: 5.157

8.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

9.  Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.

Authors:  K Genç; D L Dona; A T Reder
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

10.  Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study.

Authors:  Y Zoukos; T N Thomaides; D Kidd; M L Cuzner; A Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.